SCHEMBL4319844

SCHEMBL4319844

Nc1cccc2c1C(=O)N(c1cc(CN3CCN(CCO)CC3)ccc1/C=C/c1n[nH]c3ccccc13)C2=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 3/20 0.39
PDGFRB P09619 2/20 0.39
KDR P35968 2/20 0.39
AURKB Q96GD4 7/20 0.39
AURKA O14965 4/20 0.39
FLT1 P17948 2/20 0.38
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
PKM P14618 1/20 0.35
MAPT P10636 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
ACHE P22303 1/20 0.35
CHEK1 O14757 2/20 0.33
HTR1A P08908 1/20 0.33
DRD2 P14416 1/20 0.33
MAP4K4 O95819 2/20 0.33
NTRK1 P04629 2/20 0.33
FLT3 P36888 2/20 0.33
PLK4 O00444 2/20 0.33
PDCD1 Q15116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319850 1.00 FGFR1 (0.39) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4310125 0.95 FGFR1 (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4310121 0.95 FGFR1 (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4309562 0.89 ACHE (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4309554 0.89 ACHE (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4316652 0.87 AURKB (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4316658 0.87 AURKB (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4312103 0.85 ACHE (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4312095 0.85 ACHE (0.38) FGFR1PDGFRBKDRAURKBAURKA
SCHEMBL4317084 0.83 AURKB (0.37) FGFR1PDGFRBKDRAURKBAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 FGFR1 18/4885PDGFRB 167/4885KDR 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.